Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 3;19(1):4.
doi: 10.1186/s12885-018-5235-3.

Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil

Deborah Porto Cotrim  1 , Adriana Regina Gonçalves Ribeiro  1 , Daniele Paixão  2 , Diogo Cordeiro de Queiroz Soares  2 , Rima Jbili  2 , Natasha Carvalho Pandolfi  1 , Camila Cezana  1 , Carine de Cássia Mauro  1 , Henrique Mantoan  3 , Graziele Bovolim  4 , Louise de Brot  4 , Giovana Tardin Torrezan  5 , Dirce Maria Carraro  5 , Glauco Baiocchi  3 , Maria Nirvana da Cruz Formiga  1   2 , Alexandre A B A da Costa  6   7
Affiliations

Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil

Deborah Porto Cotrim et al. BMC Cancer. .

Abstract

Background: BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil.

Methods: In this retrospective study we evaluated clinical characteristics and BRCA1/2 genetic test results from patients with ovarian carcinoma who underwent genetic counseling at A.C.Camargo Cancer Center (Brazil) between 2015 and 2017 and had performed germline genetic testing of BRCA1/2 genes.

Results: Among 158 patients, 33 P and LP variants and were found (20.8%), 27 in BRCA1 and six in BRCA2, and six variants of unknown clinical significance (VUS). Thirteen percent of the patients did not have Multiplex Ligation-dependent Probe Amplification (MLPA) results. Three P variants in BRCA1 were found in more than one patient: c.5266dupC (p.Gln1756Profs*74), c.3331_3334delCAAG (p.Gln1111Asnfs5*), and c.211A > G (p.Arg71Gly). One LP variant in BRCA1 had not been previously described, c.4153_4154delCT (p.Leu1385Ilefs*5). Patients with previous diagnosis of breast cancer were carriers of P or LP variant in 8 of 12 cases (66.7%), and patients with a family history of ovarian or breast cancer in first- or second-degree relatives were carriers of P or LP variant in 26.7% of cases compared to 16.9% for patients without family history (p = 0.166).

Conclusion: Prevalence of BRCA1/2 germline P and LP variants is slightly higher than previously described by the largest occidental studies, with a high prevalence of variant c.5266dupC (p.Gln1756Profs*74) in BRCA1 observed. Moreover, we identified a new LP variant.

Keywords: BRCA1 and BRCA2 germline mutations; Brazil; Ovarian cancer; Prevalence.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The A.C. Camargo Cancer Center Ethics Committee approved the study (CEP# 2450/17). The need for informed consent has been waived by the A.C. Camargo Cancer Center Ethics Committee.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flowchart representative of the inclusion criteria adopted in the study
Fig. 2
Fig. 2
Frequency of pathogenic or likely pathogenic variants in BRCA1 and BRCA2 according to clinical characteristics
Fig. 3
Fig. 3
a Overall survival according to BRCA status, b Progression free survival according to BRCA status, c Frequency of platinum sensitive recurrence at first recurrence, and after second recurrence following the first platinum sensitive recurrence according to BRCA status. BRCAmut = pathogenic or likely pathogenic variant. BRCAwt = no pathogenic or likely pathogenic variants
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Instituto Nacional De Câncer (Brasil) Estimativa 2018. Incidência do Câncer no Brasil. Rio de Janeiro: INCA; 2018.
    1. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi K, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–956. doi: 10.1016/S0140-6736(15)01224-6. - DOI - PMC - PubMed
    1. Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of stage shift in women diagnosed with ovarian Cancer during phase II of the United Kingdom familial ovarian Cancer screening study. J Clin Oncol. 2017;35:1411–1420. doi: 10.1200/JCO.2016.69.9330. - DOI - PMC - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1and BRCA2Mutation carriers. JAMA. 2017;317:2402–2415. doi: 10.1001/jama.2017.7112. - DOI - PubMed

MeSH terms